Track record · closed signal

Stoke Therapeutics, Inc. (STOK) — closed signal from October 2, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on December 31, 2025.

Predicted vs. what happened

STOK price · publication thesis → realized outcomesplit-adjusted
$23.95 Published $30.66 Target $31.74 Window close $38.69 Peak
$23.00 – $24.00Entry zone — fair-value band
$23.95Published — price the day we called it
$30.66Target — the price the thesis aimed for
$38.69Peak — highest point inside the window, not a realized return
$31.74Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 6 days.

Peak price
$38.69
peak on October 16, 2025 — not a realized return
Peak gain
+61.6%
peak, from the publication price
Window close
$31.74
end-of-window price, context only
Days to target
6
Window
October 2, 2025 – December 31, 2025

The thesis — published October 2, 2025

Predicted growth
+28%
over the measurement window
Target price
$30.66
the price the thesis aimed for
Entry zone
$23.00 – $24.00
the fair-value band we waited for
Price at publication
$23.95
published October 2, 2025
Confidence
88%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

This looks set up for a short-term bounce over the next few months. Many traders see the stock as beaten down while the overall trend has not broken. Fresh results with Biogen for the Dravet drug zorevunersen revived attention and interest. The recent average price is still edging up, and early turns often show up in price before slower gauges do. This is a risky area, so plan your risk and be ready to exit if the price falls below the base.

Primary drivers

  • New Biogen-partnered data for zorevunersen boosted confidence in the drug
  • Stock appears washed out, which often leads to a short, tradable bounce
  • Positive investor mood can help prices drift back toward normal levels
  • Near-term outlook for biotech as a group looks steadier than before

How it played out

STOK: target reached in 6 days

Lyra published STOK at $23.95 on 2025-10-02 for a short-term window through 2025-12-31. The thesis expected 28% growth toward $30.66. It pointed to Biogen-partnered zorevunersen data, a washed-out setup, improving investor mood, and a steadier near-term biotech backdrop.

The move did more than the thesis required. STOK reached the target in 6 days and later peaked at $38.69 on 2025-10-16, with a 61.6% peak gain. It ended the window at $31.74, still above the target. The published thesis played out.

What happened during the window

On Nov. 4, 2025, Stoke released third-quarter results, according to Investor's Business Daily. On Dec. 16, 2025, the same article said revenue rose 117% to $10.6 million and the loss was 65 cents per share.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All STOK signals